Literature DB >> 12771111

Analysis of generic nevirapine products in developing countries.

Scott R Penzak, Edward P Acosta, Michele Turner, Jorge A Tavel, Henry Masur.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12771111     DOI： 10.1001/jama.289.20.2648-c

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

Review 1.  Substandard/counterfeit antimicrobial drugs.

Authors:  Theodoros Kelesidis; Matthew E Falagas
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

2.  A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.

Authors:  Nils von Hentig; Amina Carlebach; Peter Gute; Gaby Knecht; Stefan Klauke; Maren Rohrbacher; Hartmut Stocker; Michael Kurowski; Sebastian Harder; Schlomo Staszewski; Annette Haberl
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

3.  Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.

Authors:  Amanda H Corbett; Mina C Hosseinipour; Jean Nyirenda; Cecelia Kanyama; Naser L Rezk; Pax Mkupani; Dorothy Sichali; Hsiao Tien; Angela Dm Kashuba; Charles Mwansambo; Ralf Weigel; Peter Kazembe
Journal:  Antivir Ther       Date:  2010

4.  Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.

Authors:  Jeffrey S A Stringer; Albert J Mwango; Mark J Giganti; Lloyd Mulenga; Jens W Levy; Elizabeth M Stringer; Priscilla Mulenga; Michael S Saag; Patrick Musonda; Frank B Williams; Stewart E Reid; Benjamin H Chi
Journal:  Int J Epidemiol       Date:  2012-04       Impact factor: 7.196

5.  Antiretroviral therapy supply chain quality control and assurance in improving people living with HIV therapeutic outcomes in Cameroon.

Authors:  M P Ngogang Djobet; David Singhe; Julienne Lohoue; Christopher Kuaban; Jeanne Ngogang; Ernest Tambo
Journal:  AIDS Res Ther       Date:  2017-04-04       Impact factor: 2.250
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.